Dexcom on Tuesday announced that its new over-the-counter continuous glucose ... While Dexcom's existing G7 CGM system is available to this population, patients have to get a prescription for ...

Dexcom launched the Stelo over-the-counter CGM and announced that the 15-day G7 system, cleared by the FDA, will be launched in the second half of 2025. The new system is expected to offer ...

DexCom recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose Monitoring System ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the ...

carry-over and spillage. The letter also noted that the company does not monitor how acetaminophen affects glucose sensing with its G7 monitors. The FDA also said Dexcom is not properly evaluating ...

announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes in the United States. With an overall MARD of 8.0% ...

She is also a Certified Stress Management Coach. The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes.

growing 7% year-over-year. The company reported strong performance in regions like Japan and France, driven by expanded type 2 coverage and growth of the Dexcom ONE platform. Gross profit margin ...